What Researchers Did
Researchers investigated how well a specific intravenous drug delivery device, the Baxter infusor LV10, performed under hyperbaric conditions compared to normal room pressure.
What They Found
The study found no significant difference in the amount of fluid delivered by the Baxter infusor LV10 devices when tested under hyperbaric conditions of 243 kPa compared to normal room pressure. Despite this, the flow rates measured in both the hyperbaric and control groups were 35% lower than the manufacturer's expected rates.
What This Means for Canadian Patients
For Canadian patients undergoing hyperbaric oxygen therapy who require continuous intravenous medications, this study suggests that the Baxter infusor LV10 device can deliver drugs consistently under pressure. This is important for ensuring patients receive their prescribed treatments reliably during HBOT sessions for various conditions.
Canadian Relevance
This study was not conducted by Canadian authors or in Canada. However, the findings are relevant to the safe administration of intravenous medications during hyperbaric oxygen therapy, which is used in Canada for Health Canada-recognized indications such as delayed radiation injury and diabetic foot ulcers.
Study Limitations
A limitation of this study is that the overall flow rates for the devices were 35% lower than expected, possibly due to the test environment's temperature and the use of older devices.